July 2026
DMT
What July 2026's 10 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.
In July 2026, research on DMT reported positive effects on emotional processing, well-being, and neural plasticity, but evidence is mixed regarding its comparative efficacy and long-term durability. A placebo-controlled trial found that a harmine+DMT combination reduced embarrassment and shame, while open-label data showed sustained improvements in anxiety, life satisfaction, and quality of life in patients with depression. However, animal data indicated that DMT's antidepressant effects were comparable to S-ketamine but not consistently superior, and the overall evidence base remains limited by small samples, open-label designs, and early-stage trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers. 2026 | randomized, double-blind, placebo-controlled crossover trial | 28 | Supports | Combined harmine and DMT significantly reduced embarrassment and shame compared to placebo during a social self-evaluation task, whereas harmine alone did not. |
| Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms 2026 | review | Supports | Argues that recent patent applications for selective 5-HT2A activators, precision aerosol delivery, and structured 5-MeO-DMT regimens indicate a convergence toward scalable and safer psychedelic therapeutics. | |
| Study 35070 | in vitro experimental study | Supports | Brief 24-hour DMT exposure increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated neurotrophin expression including BDNF. | |
| Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT) in Human Neural Stem Cells. 2026 | in vitro experimental study | Supports | 24-hour DMT treatment increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated G1 cell-cycle regulators and BDNF expression. | |
| Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression 2026 | open-label clinical trial | 41 | Supports | Inhaled DMT with psychological support was associated with reduced state anxiety, increased life satisfaction, and sustained improvements in quality of life in patients with treatment-resistant depression over 12 months. |
| DMT and Microtubule Coherence Selection: A Testable Model of Informational Throttling in Time Perception 2026 | theoretical or philosophical paper | Unclear | Argues that DMT alters subjective time by modulating microtubule vibrational coherence through 5-HT2A and sigma-1 receptor pathways, slowing a scalar clock field phi. | |
| N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine. 2026 | animal study | Supports | DMT was as effective as S-ketamine in producing rapid and long-lasting antidepressant effects in helpless mice and also showed anxiolytic-like effects. | |
| Reconstituting a two-step pathway for N,N-dimethyltryptamine (DMT) biosynthesis in bacteria 2026 | experimental study | Supports | Reconstructing a two-step bacterial pathway in E. coli produced up to 103 mg/L DMT in complex medium, with methionine supplementation increasing yields 2.8-fold and identifying methylation capacity as a key constraint. | |
| Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review. 2026 | systematic review | 26 | Mixed | The registry landscape for DMT and ayahuasca trials expanded after 2020-2021, dominated by early-stage development with conservative eligibility criteria and a focus on acute safety and subjective effects, while disorder-specific programs beyond depression remain limited. |
| DMT und Ayahuasca / DMT and Ayahuasca 2026 | scientific overview | Unclear | Provides a transdisciplinary overview of DMT and ayahuasca, highlighting five unique features including oral inactivity without an MAO inhibitor, ultra-short duration, ayahuasca as a plant combination, endogenous occurrence, and the Gonzales v. O Centro ruling. |
Combined harmine and DMT significantly reduced embarrassment and shame compared to placebo during a social self-evaluation task, whereas harmine alone did not.
randomized, double-blind, placebo-controlled crossover trial Sample size: 28
Argues that recent patent applications for selective 5-HT2A activators, precision aerosol delivery, and structured 5-MeO-DMT regimens indicate a convergence toward scalable and safer psychedelic therapeutics.
review
Brief 24-hour DMT exposure increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated neurotrophin expression including BDNF.
in vitro experimental study
24-hour DMT treatment increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated G1 cell-cycle regulators and BDNF expression.
in vitro experimental study
Inhaled DMT with psychological support was associated with reduced state anxiety, increased life satisfaction, and sustained improvements in quality of life in patients with treatment-resistant depression over 12 months.
open-label clinical trial Sample size: 41
Argues that DMT alters subjective time by modulating microtubule vibrational coherence through 5-HT2A and sigma-1 receptor pathways, slowing a scalar clock field phi.
theoretical or philosophical paper
DMT was as effective as S-ketamine in producing rapid and long-lasting antidepressant effects in helpless mice and also showed anxiolytic-like effects.
animal study
Reconstructing a two-step bacterial pathway in E. coli produced up to 103 mg/L DMT in complex medium, with methionine supplementation increasing yields 2.8-fold and identifying methylation capacity as a key constraint.
experimental study
The registry landscape for DMT and ayahuasca trials expanded after 2020-2021, dominated by early-stage development with conservative eligibility criteria and a focus on acute safety and subjective effects, while disorder-specific programs beyond depression remain limited.
systematic review Sample size: 26
Provides a transdisciplinary overview of DMT and ayahuasca, highlighting five unique features including oral inactivity without an MAO inhibitor, ultra-short duration, ayahuasca as a plant combination, endogenous occurrence, and the Gonzales v. O Centro ruling.
scientific overview
Points of agreement
- DMT shows potential for reducing negative emotions and improving well-being in clinical and preclinical studies.
- DMT promotes neural plasticity, as evidenced by increased proliferation of human neural stem cells and upregulation of BDNF.
- The clinical trial landscape for DMT is expanding but remains early-stage, focusing on safety and subjective effects.
Conflicts
- One study found DMT reduced embarrassment and shame, while another found no significant difference between DMT and harmine alone on these measures.
- Animal data showed DMT's antidepressant effects lasted longer than S-ketamine in some tests, but S-ketamine had longer-lasting effects in others.
- The theoretical model proposes a mechanism for DMT's effects on time perception, but this is not empirically validated and contrasts with more conventional neuroplasticity explanations.
Gaps
- Long-term durability of DMT's effects beyond 12 months is not established.
- Most clinical trials are open-label or early-phase, lacking blinded, controlled designs for efficacy.
- The in vitro and animal findings may not translate to humans, and the optimal dose and administration route remain unclear.
- The theoretical model lacks empirical testing and validation.
- The scoping review notes limited disorder-specific programs beyond depression, indicating a gap in research for other psychiatric conditions.